Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

WAGA ENERGY Stock Bullish Momentum With A 21% Rise In The Last 10 Sessions

Loading stream...

(vianews) - shares of waga energy (cac 40: waga.pa) jumped by a staggering 21% in 10 sessions from €21.9 to €26.50 at 17:06 est on wednesday, after two successive sessions in a row of losses. cac 40 is dropping 0.09% to €7,202.70, following the last session's upward trend.

about waga energy

waga energy société anonyme, together with its subsidiaries, develops biomethane injections projects serving the energy transitions. it is involved in the design, development, financing, construction, installation, and exploitation solutions, as well as sale of biomethane. the company was incorporated in 2015 and is headquartered in meylan, france.

earnings per share

as for profitability, waga energy has a trailing twelve months eps of €-0.51.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, waga energy's stock is considered to be overbought (>=80).

more news about waga energy (waga.pa).

Categories

stockMarket

Tags

Stock PriceWAGA.PAMarket Session NowStock Market NowPrice UpMarket SessionStock Price UpWAGA ENERGYStock MarketStock
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com